“Where Innovation Meets Unmet Needs”
Amaterasu Innovations Pvt. Ltd. (AIPL) is an innovative pharmaceutical R&D company headquartered in Mumbai, dedicated to developing transformative therapies for some of the world’s most urgent and underserved medical needs. Our focus areas are:
Where innovation can make a profound difference for millions of patients worldwide.
To research, develop, and deliver innovative pharmaceutical products that enhance treatment outcomes and quality of life for patients worldwide, collaborating with academia & healthcare partners to ensure the innovation, efficacy, and accessibility
To be the India’s most significant pharmaceutical innovator in drug delivery, transforming patient care by setting new standards in industry academia collaboration, therapeutic effectiveness and accessibility, that has ability to shaping a healthier future for communities across the globe
Many active ingredients are poorly soluble in water or oil, limiting their bioavailability and effectiveness.
The stratum corneum (outermost skin layer) is a major barrier, often preventing the drug from reaching deeper skin layers or systemic circulation.
Traditional formulations may have uneven or uncontrolled drug release, leading to reduced therapeutic efficacy.
Conventional emulsions and creams can suffer from phase separation, sedimentation, or degradation over time, reducing shelf-life and potency.
Some formulations can cause irritation, greasiness, local reactions (e.g., redness, stinging), or be cosmetically unappealing.
Functional skincare topical products for wounds, psoriasis, eczema, and other inflammatory or barrier-compromised conditions are increasingly leveraging microemulsion and nanoemulsion technologies to enhance therapeutic outcomes. These advanced delivery systems improve penetration of active ingredients, ensure uniform dispersion, and promote sustained release at the target site. Their small droplet size enhances bioavailability, hydration, and skin barrier repair, while minimizing irritation—crucial for sensitive or diseased skin. Nanoemulsions can also incorporate both hydrophilic and lipophilic actives, enabling multifunctional formulations that combine anti-inflammatory, antimicrobial, and healing properties for faster and more effective recovery.
Post-operative and traumatic pain often requires frequent dosing, leading to pain spikes, poor adherence, and increased risk of side effects. In chronic neuropsychiatric and neurological conditions, fluctuating plasma drug levels and poor patient compliance remain major treatment challenges.
Muscle membrane instability and limited treatment effectiveness across diverse genetic mutations present significant challenges in managing cardiac and respiratory muscle dysfunction in Duchenne Muscular Dystrophy (DMD). These issues contribute to reduced quality of life and life expectancy for patients.
At AIPL, we are redefining the future of healthcare from India, delivering hope, healing, and transformative therapies to patients worldwide.
We’ll develop technologies that will significantly improve topical drug delivery by - enhancing solubility, skin penetration, ensure stability, and provide patient comfort.
Long-acting monthly depot injections improve patient adherence, reduce relapse rates, lower caregiver burden, minimize daily pill fatigue, provide steady drug levels, enhance symptom control, and decrease risk of missed doses. There by ensuring better outcomes.
Poloxamer 188 injection offers Duchenne muscular dystrophy patients a novel option to protect muscle membranes, improve respiratory and cardiac function, reduce muscle damage, and enhance quality of life—benefiting those currently lacking effective drug therapies for disease management
Expertise, experience, and empathy power our innovation.
Scientists, clinicians, and regulatory professionals led by a promoter with over four decades of experience in new drug delivery systems
Commitment to affordability and accessibility, ensuring breakthroughs reach those who need them most
All R&D and manufacturing processes aligned with international regulatory and quality benchmarks
At AIPL, we are redefining the future of healthcare from India, delivering hope, healing, and transformative therapies to patients worldwide.
The company’s founder, Maharukh T Rustomjee is a leading scientific figure in research and development, pharmaceutical product innovation, product formulation, manufacturing innovation and regulatory sciences. She has an enviable track record of innovations across Formulations and Drug Delivery Systems. In a career spanning 40 years, she has worked with leading organisations like Novartis, Ciba-Geigy, GSK and Burroughs Welcome going on to co found Rubicon Research – India’s pioneering contract research and drug delivery company.